LoginSignup
image de profil
Aktien Stammtisch
@Aktien_Stammtisch
11Mo·

$ABBV (-0,1 %)
AbbVie Reports Phase 2 EMPOWER Trials For Emraclidine In Schizophrenia Miss Primary Endpoint; Treatment Well-Tolerated, Further Data Analysis Underway


$BMY (-0,97 %) Bristol-Myers Squibb seems to benefits from this +13%

10
11 Commentaires
Sebastian@Baisse-Jumper
11Mo
Should it go down another 10%-15% at $ABBV: 🛒🛒🛒🛒
•
8
•
image de profil
Iwas M.@SSIT
11Mo
If AbbVie goes down even further, I might spontaneously get in today ^^
•
2
•
Utilisateur supprimé
11Mo
Le commentaire a été supprimé
image de profil
Iwas M.@SSIT
11Mo
@Memo0606 I was a fool and opted for Johnson & Johnson when both values were around 140€ 😭 This value has simply burned itself into me.
••
Utilisateur supprimé
11Mo
Le commentaire a été supprimé
Sebastian@Baisse-Jumper
11Mo
@Memo0606 Not even yet. $ABBV already has a higher dividend yield and growth is also better. Nevertheless, $JNJ is already a good share.
•
1
•
image de profil
Thomas@WolfofNersingen
11Mo
Am in
•
1
•
image de profil
Vertriebsliebhaber@Vertriebsliebhaber
11Mo
Hach, 30% at $BMY in 6 months. I can live with that 🥳😎
•
2
•
image de profil
SanSebastian@WarrenamBuffet
11Mo
stupid :(
••
image de profil
Stefan@Slucks87
11Mo
Gut :)
••
Proolix@Proolix
11Mo
Hm... in my overview AbbVie is shown with minus 20%. If I go to the share with minus 12% ... 🤷‍♀️ is this a known error or what is the reason for this? 🤷‍♀️
••
Participez à la conversation
S'inscrireConnexion